Phase 2 attrition jumps amid widespread scale-back in overall clinical trial activity: study

The wave of pipeline prioritization initiatives implemented last year has shown up in the data, with Phesi tracking a jump in terminations of phase 2 clinical trials and a fall in activity in certain major therapeutic areas.